Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
Analysis
All Analysis
AI Tech
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Economy
Editors' Picks
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Interest Rates
Investing Strategy
IPOs
Long Ideas
Magnificent 7
Market Outlook
Micro-Caps
Mutual Funds
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Undercovered Stocks
Utilities
Value
Weight Loss
Latest Healthcare & Biotech Stock Analyses
ProPhase Labs: Hidden Gem With An AI Kicker
Editas Medicine: Promising Milestone Achieved But Be Patient
Pfizer: Best Trading Momentum Since 2021 And 6% Yield
Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB
Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts
AngioDynamics: A Story To Monitor
Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity
Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug
What Has Verano So Optimistic About The Cannabis Industry?
Medtronic: Looking Ahead To FY 2025 EPS Growth, Shareholder Friendly Actions
Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
Dexcom: Positive Catalysts Ahead To Support Growth
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Iovance Biotherapeutics' Amtagvi: Innovative Therapy, Financial Strain (Rating Downgrade)
Cigna: An Up-And-Coming Dividend Growth Stock To Buy Now
Planet 13 Is The Best American Cannabis Stock
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
Hologic: Women's Health Play Looks Healthier Itself
Fortrea Holdings: Still Many Question Marks On This CRO Play
Novavax: Sanofi Partnership Revitalizes My Magnum Opus
Masimo: Promising Developments
A Strong Buy - Actinium Pharmaceuticals Promising AML Treatment With Targeted Radiotherapies
MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner
IGM Biosciences: Unlikely To Move The Needle Again In 2024
West Pharmaceutical: Pick And Shovels Of The Injectable Drug Industry
Organon Graduates From Spinoff Skepticism, With A Yield Above 5%
AdaptHealth Is Too Strong To Be Valued At 40% Of Revenues
Emergent BioSolutions: High-Risk, High-Reward Strategic Turnaround
Celldex Therapeutics: Rising High, With Room For Further Growth
Alphatec: Continued Losses Cause Continued Dilution
Merck: The Worst Has Been Avoided (Rating Upgrade)
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
Y-mAbs: There's A Ceiling Here Somewhere
Verano Holdings: Near-Term Potential Regulatory Change Would Unlock Significant Value
Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired
10 Solid Reasons To Buy Hims & Hers Stock
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
1
2
3
4
5
Next
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.